Structure via PubChem · Public domain (PubChem)
brexpiprazole
Sign in to saveAlso known as OPC 34712, OPC-34712
Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease.
Key facts
- Drug.MedlinePlus
- a615046
- Drug.image
- Brexpiprazole.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250
- Drug.image2
- Brexpiprazole_3D_ball-and-stick.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 240
- Drug.tradename
- Rexulti, Rxulti, others
- Drug.DailyMedID
- Brexpiprazole
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- By mouth
- Drug.class
- Atypical antipsychotic
- Drug.ATC_prefix
- N05
- Drug.ATC_suffix
- AX16
- Drug.legal_AU
- S4
- Drug.legal_BR
- C1
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
via Wikipedia infobox
Chemical data
- Formula
- C25H27N3O2S
- Molecular weight
- 433.6 g/mol
- IUPAC name
- 7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one
- SMILES
- C1CN(CCN1CCCCOC2=CC3=C(C=C2)C=CC(=O)N3)C4=C5C=CSC5=CC=C4
- InChIKey
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N
- XLogP
- 4.7
- Polar surface area
- 73.1 Ų
- H-bond donors
- 1
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Research
598 papers- Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
- Brexpiprazole.2012
- Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial.JAMA neurology · 2023
- Brexpiprazole.The Annals of pharmacotherapy · 2017
- Brexpiprazole and Sertraline Combination Treatment in Posttraumatic Stress Disorder: A Phase 3 Randomized Clinical Trial.JAMA psychiatry · 2025
via PubMed
~9 min read
Encyclopedic overview
22 sectionsContents
- Medical uses
- Side effects
- Pharmacology
- Pharmacodynamics
- History
- Clinical trials
- Major depressive disorder
- Phase II
- Phase III
- Adult attention deficit hyperactivity disorder
- Schizophrenia
- Phase I
- Phase II
- Phase III
- Agitation associated with dementia due to Alzheimer's disease
- Society and culture
- Legal status
- Economics
- Patents
- Research
- References
- External links
Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease.
The most common side effects include akathisia (a constant urge to move) and weight gain. The most common side effects among people with agitation associated with dementia due to Alzheimer's disease include headache, dizziness, urinary tract infection, nasopharyngitis, and sleep disturbances (both somnolence and insomnia).
Excerpted from Wikipedia’s “brexpiprazole” article, available under the CC BY-SA 4.0 licence.